Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Journal Sections
    • Subscriptions
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Collections
      • COVID-19 & Cancer Resource Center
      • Clinical Trials
      • Immuno-oncology
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
    • Journal Press Releases
  • COVID-19
  • Webinars
  • 10th Anniversary
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Cancer Discovery
Cancer Discovery
  • Home
  • About
    • The Journal
    • AACR Journals
    • Journal Sections
    • Subscriptions
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Collections
      • COVID-19 & Cancer Resource Center
      • Clinical Trials
      • Immuno-oncology
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
    • Journal Press Releases
  • COVID-19
  • Webinars
  • 10th Anniversary
  • Search More

    Advanced Search

Research Watch

Deletion of LATS1/2 Hippo Pathway Kinases Enhances Antitumor Immunity

DOI: 10.1158/2159-8290.CD-RW2016-236 Published February 2017
  • Article
  • Info & Metrics
Loading
  • Major finding: LATS1/2 loss enhances tumor immunogenicity to promote antitumor immune responses and tumor regression.

  • Mechanism: LATS1/2-deficient cells secrete nucleic acid–rich extracellular vesicles that promote IFN signaling.

  • Impact: The Hippo pathway proteins LATS1/2 have an oncogenic role in suppressing antitumor immunity.

Hippo pathway activation results in phosphorylation and activation of the LATS1/2 kinases, which phosphorylate and inactivate the YAP/TAZ transcriptional coactivators. This pathway is generally considered tumor suppressive, although context-dependent oncogenic roles have been described, but the role of Hippo signaling in tumor growth in the context of an intact immune system has not been well elucidated. Moroishi and colleagues found that LATS1/2 depletion had opposing effects on tumor cell growth in vitro and in vivo, suggesting a possible effect on antitumor immunity. In vitro, loss of Lats1/2 in melanoma, head and neck squamous cell carcinoma, and breast cancer cells reduced YAP phosphorylation and enhanced anchorage-independent growth. However, in vivo, Lats1/2 deletion inhibited the growth of melanoma, head and neck squamous cell carcinoma, and breast cancer xenografts, revealing an unexpected oncogenic role for LATS1/2 in multiple tumor types. LATS1/2-deficient tumor cells displayed massive inflammatory cell infiltration, suggesting that adaptive immune responses may clear LATS1/2-deficient tumors. In vivo, LATS1/2 loss resulted in an enhanced tumor-specific humoral immune response and CD8+ T-cell activation, indicative of robust antitumor immunity. LATS1/2 loss improved tumor vaccine efficacy, with immunization with Lats1/2-deficient cells protecting against wild-type tumor growth via an adaptive immune response, demonstrating that LATS1/2 loss enhances tumor cell immunogenicity. LATS1/2 depletion results in hyperactivation of YAP/TAZ, and, similarly, overexpression of YAP or TAZ reduced tumor growth in vivo, indicating that LATS1/2 loss may suppress tumor growth in part through YAP/TAZ-dependent transcription. Moreover, LATS1/2-deficient tumor cells secreted nucleic-acid rich extracellular vesicles that induced type I interferon (IFN) signaling and promoted antitumor immunity. The finding that LATS1/2 loss promotes an antitumor immune response reveals an unexpected oncogenic effect of the Hippo pathway kinases and suggests the possibility of targeting LATS1/2 in cancer immunotherapy.

Moroishi T, Hayashi T, Pan WW, Fujita Y, Holt MV, Qin J, et al. The Hippo pathway kinases LATS1/2 suppress cancer immunity. Cell 2016 Dec 1 [Epub ahead of print].

  • ©2016 American Association for Cancer Research.
PreviousNext
Back to top
Cancer Discovery: 7 (2)
February 2017
Volume 7, Issue 2
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Editorial Board (PDF)

Sign up for alerts

View this article with LENS

Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Discovery article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Deletion of LATS1/2 Hippo Pathway Kinases Enhances Antitumor Immunity
(Your Name) has forwarded a page to you from Cancer Discovery
(Your Name) thought you would be interested in this article in Cancer Discovery.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Deletion of LATS1/2 Hippo Pathway Kinases Enhances Antitumor Immunity
Cancer Discov February 1 2017 (7) (2) OF8; DOI: 10.1158/2159-8290.CD-RW2016-236

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Deletion of LATS1/2 Hippo Pathway Kinases Enhances Antitumor Immunity
Cancer Discov February 1 2017 (7) (2) OF8; DOI: 10.1158/2159-8290.CD-RW2016-236
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
  • Info & Metrics
Advertisement

Related Articles

Cited By...

More in this TOC Section

Research Watch

  • In Vivo CRISPR Screen Identifies FLI1 as Regulator of Effector T Cells
  • Trial Supports Combination Treatment and New Target for Multiple Myeloma
  • Mitochondrial DNA Damage Triggers an IFN-Mediated Immune Response
Show more Research Watch

Immunology

  • Epstein–Barr Virus–Induced Antitumor Immune Response May Be Harnessable
  • NK Cells Mediate T-cell Inflammation in the Tumor Microenvironment
  • MEK Inhibition Acts on CD8+ T Cells to Enhance Antitumor Immunity
Show more Immunology
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook   Twitter   LinkedIn   YouTube   RSS

Articles

  • OnlineFirst
  • Current Issue
  • Past Issues

Info For

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About Cancer Discovery

  • About the Journal
  • Editors
  • Journal Sections
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Cancer Discovery
eISSN: 2159-8290
ISSN: 2159-8274

Advertisement